Integrated analysis of circulating tumour cells and circulating tumour DNA to detect minimal residual disease in hepatocellular carcinoma

Here, we demonstrated that an integrated strategy of monitoring circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) could accurately detect minimal residual disease (MRD) and precisely predict recurrence in patients with HCC.5–7 A total of 80 patients with HCC were enrolled in this study, and 66 were eligible for analysis using postoperative serial blood samples (Figure 1A, Figure S1; Table S1). Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 Randomized clinical trial.